XIX International AIDS Conference


MOAB03 Pharmacology of Old and New TB Drugs
  Oral Abstract Session : Track B
Venue: Session Room 6
Time: 23.07.2012, 16:30 - 18:00
Co-Chairs: Jean-François Delfraissy, France
Graeme Meintjes, South Africa
 
 

16:30
MOAB0301
Abstract
Powerpoint
Webcast
Relationship between weight, efavirenz (EFV) concentrations and virologic suppression in HIV+ patients on rifampin (RIF)-based TB treatment in the ACTG 5221 STRIDE study
A.F. Luetkemeyer1, S.L. Rosenkranz2, D. Lu2, P.S. Lizak3, P. Ive4, S. Swindells5, C.A. Benson6, B. Grinsztejn7, I.M. Sanne4, D.V. Havlir1, F. Aweeka3, Adult AIDS Clinical Trials Group A5221
1San Francisco General Hospital, University of California at San Francisco, Division of HIV/AIDS, San Francisco, United States, 2Statistical Data Analysis Center, Harvard School of Public Health, Boston, United States, 3San Francisco General Hospital, University of California at San Francisco, Department of Clinical Pharmacy, San Francisco, United States, 4University of Witswatersrand, Clinical HIV Research Unit, Johannesburg, South Africa, 5University of Nebraska at Omaha, Infectious Diseases, Omaha, United States, 6University of California at San Diego (UCSD), Division of Infectious Diseases, San Diego, United States, 7Fundação Oswaldo Cruz, STD/AIDS Clinical Research Laboratory, Rio de Janeiro, Brazil
A. Luetkemeyer, United States

16:45
MOAB0302
Abstract
Tolerability among HIV-positive persons of three months of once-weekly rifapentine + INH (3HP) versus 9 months of daily INH (9H) for treatment of latent tuberculosis infection: the PREVENT TB Study (TBTC Study 26/ACTG 5259)
T. Sterling1, C. Benson2, N. Shang3, J. Miro4, B. Grinsztejn5, R. Chaisson6, A. Lucchetti7, J. Sanchez8, N. Scott3, E. Villarino3, AIDS Clinical Trials Group, Tuberculosis Trials Consortium
1Vanderbilt University, Nashville, United States, 2University of California - San Diego (UCSD), San Diego, United States, 3Centers for Disease Control & Prevention, Atlanta, United States, 4Agencia de Salut Publica, Barcelona, Spain, 5Fundação Oswaldo Cruz, IPEC Evandro Chagas, Rio de Janeiro, Brazil, 6Johns Hopkins University, Baltimore, United States, 7Inmensa, Lima, Peru, 8Impacta, Lima, Peru
T. Sterling, United States

17:00
MOAB0303
Abstract
Powerpoint
Webcast
Efavirenz (EFV) concentrations in pregnant women taking EFV-based antiretroviral therapy (ART) with and without rifampin-containing tuberculosis (TB) treatment: the TSHEPISO Study Team
H. McIlleron1, N. Martinson2,3, P. Denti1, F. Mashabela2, J. Hunt3, S. Shembe2, J. Hull4, D.W. Haas5, R. Msandiwa2, S. Cohn3, R. Chaisson3, K.E. Dooley3, TSHEPISO Study Team
1University of Cape Town, Cape Town, South Africa, 2Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Soweto, South Africa, 3Johns Hopkins University School of Medicine, Baltimore, United States, 4Chris Hani Baragwanath Hospital and University of the Witwatersrand, Department of Obstetrics, Soweto, South Africa, 5Vanderbilt University, Nashville, United States
K. Dooley, United States

17:15
MOAB0304
Abstract
Powerpoint
Webcast
Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentin
D. Everitt1, H. Winter2, E. Egizi1
1TB Alliance, New York, United States, 2University of Otago, Dunedin, New Zealand
D. Everitt, United States

17:30
MOAB0305
Abstract
Powerpoint
Webcast
A phase 2 trial of novel anti-tuberculosis regimens with increased efficacy and low potential to interact adversely with antiretroviral therapy
D. Everitt1, S. Murray2, A. Diacon3, R. Dawson4, J. Hutchings4, C. Van Niekerk5, E. Egizi2, P. Becker6
1TB Alliance, Research & Development, New York, United States, 2TB Alliance, New York, United States, 3Stellenbosch University, Cape Town, South Africa, 4University of Cape Town, Cape Town, South Africa, 5TB Alliance, Pretoria, South Africa, 6Medical Research Council of South Africa, Johannesburg, South Africa
S. Murray, United States

Powerpoints presentations
Relationship between weight, efavirenz (EFV) concentrations and virologic suppression in HIV+ patients on rifampin (RIF)-based TB treatment in the ACTG 5221 STRIDE study - Anne F. Luetkemeyer

Efavirenz (EFV) concentrations in pregnant women taking EFV-based antiretroviral therapy (ART) with and without rifampin-containing tuberculosis (TB) treatment: the TSHEPISO Study Team - Kelly E Dooley

Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentin - Dan Everitt

A phase 2 trial of novel anti-tuberculosis regimens with increased efficacy and low potential to interact adversely with antiretroviral therapy - Stephen Murray



Rapporteur report

Track B report by Dr. Federico Pulido


MOAB03     Oral Abstract Session

Pharmacology of Old and New TB Drugs

Interesting session with presentation of new data about antiretroviral treatment in HIV infected patients with tuberculosis and about therapy of latent tuberculosis. Some of the information have direct clinical implications and a possible impact on the therapeutic guidelines.

MOAB0301:    Relationship between weight, efavirenz (EFV) concentrations and virologic suppression in HIV+ patients on rifampin (RIF)-based TB treatment in the ACTG 5221 STRIDE study
A large (n=543), international study (mostly from sub-Saharan Africa and South America) testing the impact of weight on the Cmin and the efficacy of EFV 600 mg when co-administered with RIF. Although those patients with higher weight (>50 or >60 kg) have lower levels of EFV, there is no correlation with the use of RIF nor influence on the viral response to EFV.  In black patients, Cmin of EFV is higher with RIF than without RIF. The authors conclude that these data do not support weight-based increase of EFV during rifampin-containing TB treatment

MOAB0302:  Tolerability among HIV-positive persons of three months of once-weekly rifapentine + INH (3HP) versus 9 months of daily INH (9H) for treatment of latent tuberculosis infection: the PREVENT TB Study (TBTC Study 26/ACTG 5259)
The PREVENT Study showed the non-inferiority of 3HP versus 9H for treatment of latent tuberculosis infection, but the number of HIV+ included patients was small. Now, the number of HIV+ patients has been increased (n=403) and the tolerability of both regimens in this population with high CD4 counts and not on antiretroviral therapy has been analyzed. They conclude that among HIV-infected persons, 3HP had higher treatment completion rates and was better tolerated than 9H. Data comparing efficacy in this subgroup are not yet available.

MOAB0303:  Efavirenz (EFV) concentrations in pregnant women taking EFV-based antiretroviral therapy (ART) with and without rifampin-containing tuberculosis (TB) treatment: the TSHEPISO Study Team
TSHEPISO is a prospective cohort study among HIV-infected pregnant women with TB (n=250 CASES) and without TB (n=500 CONTROLS), currently enrolling in Soweto, South Africa. Preliminary results from 76 women and 70 infants with EFV PK data were reported. Estimated Cmin among women pre/intrapartum and post-partum were not significantly different.  No differences were found between cases and controls regarding proportion of women with viral load <20 copies/mL: 70% of cases and 83% of controls, but the sample was small. No transmission was reported.


MOAB0304:  Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentin.

The new antituberculosis drug TMC207 (Bedaquiline), is a substrate of CYP3A4 enzymes, but not an inducer nor inhibitor. Rifampin and Rifapentin decrease the concentration (AUC) of bedaquiline more than 50% and they can’t be used together. Previous pK data do not shown relevant interaction with antiretrovirals, although more information could be necessary with lopinavir.


MOAB0305: A phase 2 trial of novel anti-tuberculosis regimens with increased efficacy and low potential to interact adversely with antiretroviral therapy.

Different combinations of new anti-tuberculosis drugs were evaluated in 85 patients with tuberculosis (smear and culture positive). Early response was measured by the bactericidal activity after 14 days. Results confirm those with a test performed in a mouse model. The combination of PA824+moxifloxacin+pyrazynamide shows better activity than the usual combination of 4 drugs (IREZ) and could be tested in further trials.


   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2012 International AIDS Society